Blueprint Medicines Corp Stock Market Value
| BPMC Stock | USD 86.85 2.05 2.31% |
| Symbol | Blueprint |
Blueprint Medicines Corp Price To Book Ratio
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 4.118 | Quarterly Revenue Growth 0.855 | Return On Assets (0.25) | Return On Equity (1.57) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Blueprint Medicines 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Blueprint Medicines' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Blueprint Medicines.
| 03/20/2024 |
| 04/19/2024 |
If you would invest 0.00 in Blueprint Medicines on March 20, 2024 and sell it all today you would earn a total of 0.00 from holding Blueprint Medicines Corp or generate 0.0% return on investment in Blueprint Medicines over 30 days. Blueprint Medicines is related to or competes with Terns Pharmaceuticals, Amylyx Pharmaceuticals, Acumen Pharmaceuticals, Inozyme PharmaInc, X4 Pharmaceuticals, PTC Therapeutics, and Krystal Biotech. Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blo... More
Blueprint Medicines Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Blueprint Medicines' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Blueprint Medicines Corp upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.23 | |||
| Information Ratio | 0.0407 | |||
| Maximum Drawdown | 19.44 | |||
| Value At Risk | (4.78) | |||
| Potential Upside | 4.99 |
Blueprint Medicines Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Blueprint Medicines' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Blueprint Medicines' standard deviation. In reality, there are many statistical measures that can use Blueprint Medicines historical prices to predict the future Blueprint Medicines' volatility.| Risk Adjusted Performance | 0.0462 | |||
| Jensen Alpha | 0.0311 | |||
| Total Risk Alpha | (0.12) | |||
| Sortino Ratio | 0.0413 | |||
| Treynor Ratio | 0.0699 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Blueprint Medicines' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Blueprint Medicines Corp Backtested Returns
We consider Blueprint Medicines very steady. Blueprint Medicines Corp secures Sharpe Ratio (or Efficiency) of 0.0491, which signifies that the company had a 0.0491% return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Blueprint Medicines Corp, which you can use to evaluate the volatility of the firm. Please confirm Blueprint Medicines' Downside Deviation of 3.23, risk adjusted performance of 0.0462, and Mean Deviation of 2.35 to double-check if the risk estimate we provide is consistent with the expected return of 0.16%. Blueprint Medicines has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 2.75, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Blueprint Medicines will likely underperform. Blueprint Medicines Corp right now shows a risk of 3.36%. Please confirm Blueprint Medicines Corp expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if Blueprint Medicines Corp will be following its price patterns.
Auto-correlation | -0.61 |
Very good reverse predictability
Blueprint Medicines Corp has very good reverse predictability. Overlapping area represents the amount of predictability between Blueprint Medicines time series from 20th of March 2024 to 4th of April 2024 and 4th of April 2024 to 19th of April 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Blueprint Medicines Corp price movement. The serial correlation of -0.61 indicates that roughly 61.0% of current Blueprint Medicines price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.61 | |
| Spearman Rank Test | -0.68 | |
| Residual Average | 0.0 | |
| Price Variance | 5.73 |
Blueprint Medicines Corp lagged returns against current returns
Autocorrelation, which is Blueprint Medicines stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Blueprint Medicines' stock expected returns. We can calculate the autocorrelation of Blueprint Medicines returns to help us make a trade decision. For example, suppose you find that Blueprint Medicines has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Blueprint Medicines regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Blueprint Medicines stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Blueprint Medicines stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Blueprint Medicines stock over time.
Current vs Lagged Prices |
| Timeline |
Blueprint Medicines Lagged Returns
When evaluating Blueprint Medicines' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Blueprint Medicines stock have on its future price. Blueprint Medicines autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Blueprint Medicines autocorrelation shows the relationship between Blueprint Medicines stock current value and its past values and can show if there is a momentum factor associated with investing in Blueprint Medicines Corp.
Regressed Prices |
| Timeline |
Pair Trading with Blueprint Medicines
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Blueprint Medicines position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will appreciate offsetting losses from the drop in the long position's value.Moving against Blueprint Stock
| 0.51 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Blueprint Medicines could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Blueprint Medicines when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Blueprint Medicines - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Blueprint Medicines Corp to buy it.
The correlation of Blueprint Medicines is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Blueprint Medicines moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Blueprint Medicines Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Blueprint Medicines can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Blueprint Medicines Correlation, Blueprint Medicines Volatility and Blueprint Medicines Alpha and Beta module to complement your research on Blueprint Medicines. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Blueprint Medicines technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.